Key terms
About FGEN
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FGEN news
Apr 02
11:36pm ET
FibroGen (FGEN) Gets a Sell from Goldman Sachs
Mar 11
7:22am ET
FibroGen appoints Deyaa Adib as CMO
Feb 26
10:30pm ET
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
Feb 26
4:15pm ET
FibroGen, AstraZeneca terminate U.S./RoW roxadustat collaboration agreement
Feb 26
4:09pm ET
FibroGen reports Q4 EPS (57c), consensus (42c)
Feb 13
10:45pm ET
Sell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacy
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
7:16am ET
FibroGen completes pamrevlumab arm in Precision Promise Phase 2/3 trial
No recent press releases are available for FGEN
FGEN Financials
Key terms
Ad Feedback
FGEN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FGEN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
